US Patent Issued to Microvascular Therapeutics, LLC

Tucson, AZ, May 30, 2019 --(PR.com)-- Microvascular Therapeutics (MVT) has been awarded US Patent Number 10,279,053, entitled, “Microbubble Compositions, Methods of Making Same and Method of Using Same,” issued on May 7th, 2019. This patent describes a novel method of making ultra-stable microbubbles of perfluoropentane gas. Wyatt Unger, President and CEO of MVT said, “We are excited about issuance of this patent as we have discovered a new way of making ultra-stable microbubbles for ultrasound imaging, molecular imaging, and therapeutic applications of ultrasound. Previous applications of perfluoropentane for ultrasound imaging have used emulsions of this material, but we have discovered a way of making pre-formed perfluoropentane microbubbles that are highly stable for ultrasound imaging.” MVT is currently performing a clinical trial of a dose ranging study in human volunteers using a new microbubble ultrasound contrast agent, MVT-100. MVT-100 is being developed via the 505(b)(2) pathway resulting in accelerated approval for the new drug.

About Microvascular Therapeutics (MVT)
MicroVascular Therapeutics is a privately owned biotechnology company based in Tucson, Arizona and is a leader in microbubble technology. MVT’s mission is to develop the next generation of contrast agents for diagnostic ultrasound and advance the field of ultrasound for diagnosis and treatment of disease. The chemists at MVT have developed a new, patented formulation that may potentially serve as a platform for development of agents for molecular imaging and image-guided therapy. (www.mvtpharma.com)

For further information, please contact Wyatt Unger (w.unger@mvtpharma.com) at Microvascular Therapeutics.

Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.